{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:32:45Z","timestamp":1760232765402,"version":"build-2065373602"},"reference-count":58,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of antidiabetic mediations found to also reduce cardiovascular morbidity and mortality and hospitalization for heart failure. Positive results from the EMPEROR-Preserved (empagliflozin) and PRESERVED-HF (dapagliflozin) studies led to recommendations for SGLT2 inhibitors in HFpEF within major international heart failure guidelines. However, studies of ipragliflozin and luseogliflozin, agents approved outside the United States (U.S.), reported different outcomes relative to pivotal trials and failed to realize benefits in the HFpEF population. Varying definitions of HFpEF and outcomes studied complicate the interpretation of study results. SGLT2 inhibitors may cause common adverse events (genital mycotic infections, volume depletion) in addition to rare but severe sequela, including euglycemic diabetic ketoacidosis, Fournier\u2019s gangrene, and lower limb amputation. While evidence of CV benefits grows, SGLT2 inhibitor prescribing has lagged, particularly among patients without diabetes. In the U.S., high cost and administrative hurdles may contribute to decreased patient and clinician uptake of this drug class. Future trial results and clinical experience with SGLT2 inhibitors may lead to expanded use and greater uptake among patients with heart failure.<\/jats:p>","DOI":"10.3390\/pharmacy10060166","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:46:41Z","timestamp":1669798001000},"page":"166","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.3390","volume":"10","author":[{"given":"Lindsay","family":"Brust-Sisti","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-5216","authenticated-orcid":false,"given":"Nicole","family":"Rudawsky","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-0158","authenticated-orcid":false,"given":"Jimmy","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-6167","authenticated-orcid":false,"given":"Luigi","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA"},{"name":"Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_2","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2022, May 26). Story of Discovery: SGLT2 Inhibitors: Harnessing the Kidneys to Help Treat Diabetes, Available online: https:\/\/www.niddk.nih.gov\/news\/archive\/2016\/story-discovery-sglt2-inhibitors-harnessing-kidneys-help-treat-diabetes#:~:text=The%20first%20SGLT2%20inhibitor%20to,Jardiance%C2%AE)%20in%20August%202014."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"U.S. Food & Drug Administration (2022, June 01). FDA News Release: FDA Approves New Treatment for a Type of Heart Failure, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-type-heart-failure."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_11","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e156309","DOI":"10.1172\/JCI156309","article-title":"SGLT2 inhibitors: Further evidence for heart failure with preserved ejection fraction as a metabolic disease?","volume":"131","author":"Lewsey","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","article-title":"Differential Pathophysiological Mechanisms in Heart Failure with a Reduced or Preserved Ejection Fraction in Diabetes","volume":"9","author":"Packer","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/ehf2.13905","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: An updated meta-analysis","volume":"9","author":"Cao","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","article-title":"Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients with Heart Failure and Preserved Ejection Fraction","volume":"79","author":"Ferreira","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline Characteristics of Patients with HF with Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review","volume":"76","author":"Spertus","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: The CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat. Med."},{"key":"ref_25","unstructured":"Zynquista (Sotagluflozin) (2022, August 20). Guidehouse Germany GmbH (Berlin, Germany). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zynquista-epar-product-information_en.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ggi.14363","article-title":"Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study","volume":"22","author":"Akasaka","year":"2022","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e015103","DOI":"10.1161\/JAHA.119.015103","article-title":"Effect of Luseogliflozin on Heart Failure with Preserved Ejection Fraction in Patients with Diabetes Mellitus","volume":"9","author":"Ejiri","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population","volume":"28","author":"Thorvaldsen","year":"2022","journal-title":"J. Card. Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_32","unstructured":"Boehringer Ingelheim (2022, September 02). Jardiance. Available online: https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf."},{"key":"ref_33","unstructured":"Boehringer Ingelheim (2022, September 02). Jardiance. European Medicines Association Prescribing Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jardiance-epar-product-information_en.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e001238","DOI":"10.1136\/bmjdrc-2020-001238","article-title":"Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation","volume":"8","author":"McGovern","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_35","unstructured":"U.S. Food and Drug Administration (2022, June 07). Drug Safety Communication: FDA Warns that SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood, Available online: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM446954.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern with SGLT2 Inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2924","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab Res. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis","volume":"11","author":"Dutta","year":"2022","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_39","unstructured":"U.S. Food and Drug Administration (2022, July 26). Drug Safety Communication: FDA Warns about Rare Occurrences of a Serious Infection of the Genital Area with SGLT2 Inhibitors for Diabetes, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/dom.13900","article-title":"Fournier\u2019s gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials","volume":"22","author":"Silverii","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e000985","DOI":"10.1136\/bmjdrc-2019-000985","article-title":"Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier\u2019s gangrene","volume":"8","author":"Yang","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Heyward, J., Mansour, O., Olson, L., Singh, S., and Alexander, G.C. (2020). Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234065"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","article-title":"Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: Real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"118894","DOI":"10.1016\/j.watres.2022.118894","article-title":"Mass trends of parabens, triclocarban and triclosan in Arizona wastewater collected after the 2017 FDA ban on antimicrobials and during the COVID-19 pandemic","volume":"222","author":"Adhikari","year":"2022","journal-title":"Water Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e008381","DOI":"10.1161\/CIRCOUTCOMES.121.008381","article-title":"Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States","volume":"14","author":"Sangha","year":"2021","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FJC.0000000000000864","article-title":"Antihyperglycemic Therapies with Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns within an Academic Medical Center","volume":"76","author":"Hamid","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2337\/dc19-1943","article-title":"Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013\u20132018","volume":"43","author":"Dave","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-021-01316-4","article-title":"Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: Influence of renal function and heart failure diagnosis","volume":"20","author":"Hinton","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.34067\/KID.0007862021","article-title":"Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis","volume":"3","author":"Zhuo","year":"2022","journal-title":"Kidney360"},{"key":"ref_51","unstructured":"Cohen, R.A., Kirzinger, W.K., and Gindi, R.M. (2022, October 10). Strategies Used by Adults to Reduce Their Prescription Drug Costs, Available online: https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db119.pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e214205","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types","volume":"2","author":"Tummalapalli","year":"2021","journal-title":"JAMA Health Forum"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2020969","DOI":"10.1001\/jamanetworkopen.2020.20969","article-title":"Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program","volume":"3","author":"Luo","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100144","DOI":"10.1016\/j.ajpc.2020.100144","article-title":"Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice","volume":"5","author":"Warden","year":"2021","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.sapharm.2018.09.006","article-title":"Medication adherence and barriers among low-income, uninsured patients with multiple chronic conditions","volume":"15","author":"Adams","year":"2019","journal-title":"Res. Social Adm, Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s13300-021-01098-8","article-title":"Differential Cost-Sharing Undermines Treatment Adherence to Combination Therapy: Evidence from Diabetes Treatment","volume":"12","author":"Nelson","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_57","first-page":"924","article-title":"Impact of financial medication assistance on medication adherence: A systematic review","volume":"27","author":"Hung","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/j.japh.2020.07.001","article-title":"Access to medications among adults with type 2 diabetes using pharmacy- or clinic-based medication assistance programs: A systematic review","volume":"60","author":"Ward","year":"2020","journal-title":"J. Am. Pharm. Assoc."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/10\/6\/166\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:33Z","timestamp":1760146233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/10\/6\/166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["pharmacy10060166"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy10060166","relation":{},"ISSN":["2226-4787"],"issn-type":[{"type":"electronic","value":"2226-4787"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}